ImCheck’s ICT01 Earns FDA Orphan Drug Designation for AML

AML treatment ICT01 granted FDA's orphan drug status

ICT01, an immune-modulating therapy being developed by Imcheck Therapeutics for acute myeloid leukemia (AML), has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) as a potential treatment for this aggressive type of blood cancer. The FDA awards this designation to investigational treatments for diseases that affect fewer than 200,000 Americans. Its goal is to offer extra incentives for companies investing in treatme…

FDA Grants Orphan Drug Designation to ImCheck Therapeutics’ ICT01 for Acute Myeloid Leukemia Treatment

The U.S. Food and Drug Administration (FDA) has granted […]

ImCheck’s ICT01 Earns FDA Orphan Drug Designation for AML

ImCheck's ICT01 gains an orphan drug designation from the FDA, offering hope for acute myeloid leukemia (AML) treatment in older patients with limited options.

Optimizing AML Treatment: ICT01 Receives FDA Orphan Drug Designation

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.